• COVID Resilient Environment and Clinical Trials

    • Share:
    Name: COVID Resilient Environment and Clinical Trials
    Date: November 19, 2020
    Time: 12:00 PM - 1:30 PM EST
    Registration: Register Now
    Event Description:
    Our panelists will explore how COVID-19 has affected clinical trials, with an emphasis on how trials are successfully decentralizing. We’ll hear from a clinical research organization with focus on using digital health, novel trial modes, and patient networks and engagement for how a virtual trial can work practically; an attorney connected to the FDA regulation of clinical trials; a gene therapy company with an ongoing clinical trial; and a large pharma manufacturer with years of clinical experience in both vaccines and treatments. 
    • Phil Collis, Ph.D., vice President, global development, BioCryst Pharmaceuticals (moderator)
    • Amy Cramer, director, global product development strategic partnerships, Pfizer
    • Tina Papagiannopoulos, associate, Foley Hoag 
    • Kristen Pappas, associate director, bluebird bio 
    • David Tripi, vice president, innovation and customer engagement, IQVIA
    Thanks to our sponsors, BIO and IQVIA Biotech.
    Date/Time Information:
    November 19
    Noon to 1:30 p.m.
    Contact Information:
    Hosted by NCBIO, Amber Niebauer, Events Director
    Sign up here and you will receive the GoToWebinar link to complete your registration. If you have any registration questions, please contact our events director, Amber Niebauer. 

    If you are not a NCBIO member and would like to join, please contact our membership director,
    Laura Gunter.
    Set a Reminder:
    Enter your email address below to receive a reminder message.
  • Mark Your Calendars